Discontinued — last reported Q3 '23
Spinal Muscular Atrophy — Product revenues
Biogen Spinal Muscular Atrophy — Product revenues increased by 2.5% to $448.20M in Q3 2023 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration, successful patient access programs, or growth in the diagnosed patient population, while a decrease may signal increased competition, loss of exclusivity, or challenges in patient adherence.
Detailed definition
This metric represents the total net sales generated from the company's therapeutic portfolio specifically indicated for...
Peer comparison
Comparable to revenue metrics for rare disease or orphan drug segments at other biopharmaceutical companies, often evaluated based on patient prevalence and competitive landscape.
biib_segment_spinal_muscular_atrophy_product_revenuesHistorical Data
| Q2 '22 | Q3 '22 | Q2 '23 | Q3 '23 | |
|---|---|---|---|---|
| Value | $431.10M | $431.10M | $437.10M | $448.20M |
| QoQ Change | — | +0.0% | +1.4% | +2.5% |
| YoY Change | — | — | +1.4% | +4.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's spinal muscular atrophy — product revenues?
- Biogen (BIIB) reported spinal muscular atrophy — product revenues of $448.20M in Q3 2023.
- What does spinal muscular atrophy — product revenues mean?
- The total revenue earned from selling drugs used to treat Spinal Muscular Atrophy.